Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activityMore than 300,000 people in the U.S.
The US Food and Drug Administration (FDA) has accepted for review the resubmission of the supplemental biologics license application (sBLA) for Dupixent (dupilumab) to treat adults and pediatric ...
The following is a summary of “Integrative epidemiology and immuno-transcriptomics uncover a risk and potential mechanism for ...
French drug major Sanofi (SNY) and Regeneron Pharmaceuticals, Inc. (REGN) announced Friday that the U.S. Food and Drug Administration ...
Eli Lilly’s Ebglyss (lebrikizumab-lbkz) showed improvement in skin clearance and itch relief for most patients with ...
Eczema affects an estimated 20 per cent of children and 11 per cent of adults in Singapore. In its moderate to severe form, ...
A major news story from Sanofi this month is that "The European Medicines Agency has approved Dupixent (dupilumab) to treat ...
GlobalData on MSN6d
AstraZeneca and Amgen’s Tezspire succeeds in Phase III nasal polyps trialA Phase III trial with the companies’ monoclonal antibody in patients with chronic rhinosinusitis with nasal polyps met its ...
About SciBase SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care ...
Second Phase 3 Clinical Trial Again Shows Dupilumab Lessens Disease in COPD Patients With Type 2 Inflammation May 20, 2024 — Chronic obstructive pulmonary disease patients with type 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback